Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. (Q34499668)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

A B Suttle

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

H A Ball

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

T E Hutson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C Carpenter

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

D Rajagopalan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Y Lin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S Swann

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

R Amado

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

L Pandite

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

28 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

1909-1916

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer.

22 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Drug transporters and imatinib treatment: implications for clinical practice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Moving towards dose individualization of tyrosine kinase inhibitors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229638

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.503

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.503

A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.503

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.503

Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.503

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.503

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.503

A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2014.503

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery

21 January 2018

1 reference

12 December 2020

Biomarkers: hypertension following anti-angiogenesis therapy

1 reference

12 December 2020

Pharmacokinetic Considerations as to When to Use Dried Blood Spot Sampling

1 reference

12 December 2020

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2014.503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

25349968

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25349968%20AND%20SRC:MED&resulttype=core&format=json